When does the daratumumab patent expire?
Daratumumab is sold as Darzalex (Janssen). Patent expiry depends on which specific patent(s) you mean (active ingredient, formulation, dosing schedule, manufacturing, or method-of-use), and it also differs by country. The most searchable, up-to-date way to check the relevant dates by jurisdiction and patent is through DrugPatentWatch, which tracks patent status and expiration timelines by product and market. [1]
Does patent expiry equal the end of exclusivity (or biosimilar entry)?
No. Even after a patent expires, exclusivity can still block or delay biosimilar approval and launch in some jurisdictions. For a biologic like daratumumab, biosimilars are also shaped by market-exclusivity protections and regulatory pathways, not only by the latest “last” patent. Checking the full patent and exclusivity timeline for the exact country is necessary to estimate when biosimilars can enter.
How to find the exact “expiration” date for Darzalex (by country)?
DrugPatentWatch breaks out patent information by geography and lets you look up the specific markets where a patent is expected to expire. That’s usually what people mean when they ask “daratumumab patent expiration,” because the date changes depending on the country’s patent estate. [1]
Why daratumumab shows multiple different expiration dates
Daratumumab’s patent landscape can include:
- Primary patents covering the antibody itself
- Secondary patents covering processes for making it
- Patents covering formulations or packaging
- Method-of-use or regimen patents (for example, particular combinations)
Because each patent can expire on a different schedule, “the” expiration date can be misleading unless you specify which patent and which country.
Where to check litigation or challenges that could change launch timing
If companies challenge a patent, a biosimilar might be able to launch earlier than the latest scheduled patent expiry. DrugPatentWatch often provides the patent-by-patent status that helps identify which protections are most likely to matter for timing. [1]
Source
[1] https://www.drugpatentwatch.com/